摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

哌泊溴烷 | 54-91-1

中文名称
哌泊溴烷
中文别名
1,4-双(3-溴-1-氧代丙基)哌嗪
英文名称
pipobroman
英文别名
1,4-di(3-bromopropionyl)piperazine;1,4-bis-(3-bromo-propionyl)-piperazine;N,N-bis(3-bromopropionyl)piperazine;N,N'-Di-(3-brom-propionyl)-piperazin;3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
哌泊溴烷化学式
CAS
54-91-1
化学式
C10H16Br2N2O2
mdl
——
分子量
356.057
InChiKey
NJBFOOCLYDNZJN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    106-107℃
  • 沸点:
    487℃
  • 密度:
    1.691
  • 闪点:
    248℃
  • 溶解度:
    氯仿(微溶)、甲醇(微溶、加热)
  • 物理描述:
    Solid
  • 颜色/状态:
    CRYSTALS
  • 气味:
    SLIGHTLY SHARP, FRUITY ODOR
  • 味道:
    SLIGHT BITTER TASTE
  • 稳定性/保质期:
    STABLE IN LIGHT & AIR
  • 保留指数:
    2030;2050

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    40.6
  • 氢给体数:
    0
  • 氢受体数:
    2

ADMET

毒理性
  • 医疗监测
对于抗肿瘤制剂的预防措施:目前没有可用于常规监测人员接触有害药物证据的方法。检测诱变剂或染色体损伤的测试并非针对特定药物,且仅在控制性研究中具有价值。对于需要检测职业暴露的敏感度级别的尿液中存在有害药物的化学分析,目前仅限于少数药物,且尚未在商业上可用。抗肿瘤制剂。
/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ There is no method available for routine monitoring of personnel for evidence of hazardous drug exposure. Tests for the presence of mutagens or chromosomal damage are not drug specific and are of value only in controlled studies. Chemical analysis of urine for the presence of hazardous drugs at the sensitivity level needed to detect occupational exposure is limited to a few drugs and is not yet commercially available. /Antineoplastic agents/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 人类毒性摘录
包括严重贫血(部分为溶血性)和网织红细胞增多。当然,白细胞减少和血小板减少是药物预期作用的结果,但白细胞计数应保持在每立方毫米3000以上,血小板计数应保持在每立方毫米100,000以上。
ADVERSE EFFECTS INCL SEVERE ANEMIA, IN PART OF HEMOLYTIC NATURE, & RETICULOCYTOSIS. LEUKOPENIA & THROMBOCYTOPENIA, OF COURSE, ARE RESULT OF INTENDED ACTION OF DRUG, BUT LEUKOCYTE COUNT SHOULD BE KEPT ABOVE 3000/CU MM & PLATELET COUNT ABOVE 100,000/CU MM.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 人类毒性摘录
偶尔报告有不良胃肠道反应(短暂的恶心、呕吐、腹痛和腹泻)。少数患者观察到皮疹。
ADVERSE GI REACTIONS (TRANSIENT NAUSEA, VOMITING, ABDOMINAL CRAMPS, & DIARRHEA) HAVE BEEN REPORTED INFREQUENTLY. RASH HAS BEEN OBSERVED IN A FEW PATIENTS.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 人类毒性摘录
皮波布罗曼是一种高毒性的药物,治疗指数低,如果没有毒性迹象,不太可能出现治疗效果。该药物必须在经验丰富的医生监督下使用,这些医生擅长使用细胞毒性药物治疗。
Pipobroman is a highly toxic drug with a low therapeutic index, and a therapeutic response is not likely to occur without some evidence of toxicity. The drug must be used only under constant supervision by physicians experienced in therapy with cytotoxic agents.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 人类毒性摘录
皮波布罗兰的主要毒性作用是骨髓抑制,导致白细胞减少、血小板减少和贫血,表现为血红蛋白至少减少2 g/dl。骨髓抑制可能在治疗开始后4周或更长时间内不发生。通常,暂时停止使用该药物治疗已有效地控制了毒性;然而,持续性细胞减少已有报道。贫血可能在总皮波布罗兰剂量低至30 mg/kg时发生,剂量更高时可能更严重。在大多数情况下,白细胞减少伴随贫血。贫血通常对减少剂量和输血反应良好,输血量足以产生至少10 g/dl的血红蛋白水平。在几位患者中观察到了由血红蛋白迅速下降、胆红素浓度升高和网织红细胞增多提示的溶血过程。如果出现这种溶血过程的证据,应停止皮波布罗兰治疗。
Pipobroman's principal toxic effect is bone marrow depression resulting in leukopenia, thrombocytopenia, and anemia manifested by a reduction in hemoglobin of at least 2 g/dl. Depression of the bone marrow may not occur for 4 weeks or more after treatment is initiated. Usually, the temporary discontinuance of therapy with the drug has been effective in controlling toxicity; however, persistent cytopenia has been reported. Anemia may occur with total pipobroman dosage as low as 30 mg/kg and may be more severe at higher dosage. In most instances, leukopenia accompanies the anemia. Anemia usually has responded to dosage reduction and to blood transfusions in amounts sufficient to produce a hemoglobin level of at least 10 g/dl. A hemolytic process suggested by a rapid drop in hemoglobin, increased bilirubin concentrations, and reticulocytosis has been observed in several patients. If evidence of this hemolytic process develops, pipobroman therapy should be discontinued.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
  • 吸收
从胃肠道吸收良好。
Well absorbed from the GI tract.
来源:DrugBank
吸收、分配和排泄
药物口服给药后吸收良好。关于该药物在人体内的分布和命运的研究尚未见报道。
The drug is well absorbed following oral administration. Studies of its distribution and fate in man have not been reported.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 海关编码:
    2933599090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335,H351,H361
  • 储存条件:
    库房应保持通风、低温和干燥,并将货物与食品原料分开存放。

SDS

SDS:07a35a570f9588882eb0bc674b693a1c
查看

制备方法与用途

生物活性

Pipobroman 是哌嗪的溴化衍生物,是一种有效的烷基化剂。它通过抑制 DNA 和 RNA 聚合酶或减少嘧啶核苷酸掺入 DNA 发挥其作用。Pipobroman 可用于癌症研究,包括真性红细胞增多症、骨髓增生性肿瘤和急性髓系白血病(AML)。

类别

有毒物品

毒性分级

高毒

急性毒性

  • 大鼠口服 LD50: 220 毫克/公斤
  • 小鼠口服 LD50: 382 毫克/公斤

可燃性危险特性

可燃;燃烧时产生有毒氮氧化物和溴化物烟雾

储运特性

应存放在通风、低温干燥的库房中,并与食品原料分开存放。

灭火剂

干粉、泡沫、沙土、二氧化碳、雾状水

反应信息

  • 作为反应物:
    描述:
    哌泊溴烷potassium phosphate 作用下, 以 二氯甲烷N,N-二甲基甲酰胺丙酮 为溶剂, 反应 120.0h, 生成
    参考文献:
    名称:
    Synthesis and Biological Activities of Diquaternary Dipiperazinium Salts Containing Dithiocarboxyl Groups
    摘要:
    A series of diquaternary dipiperazinium salts containing dithiocarboxyl groups 6a-f and 9 were synthesized and evaluated for their analgesic and sedative activities. The result showed that the presence of two quaternary ammonium cations and the distance between them are very important for the activities of the salts. Compound 6b exhibited the best activities (at dose 2 mg/kg, analgesic, 57%; sedative, 59%) among compounds 6a-f. Compound 9 not only showed the most potent analgesic (85.4%, dose 1 mg/kg) and sedative (93.1%, dose 1 mg/kg) activities, but also exhibited anticancer activity against KB (68.7%, dose 10 muM).
    DOI:
    10.1002/1521-4184(200105)334:5<173::aid-ardp173>3.0.co;2-#
  • 作为产物:
    描述:
    哌嗪3-溴-1-丙醇 在 sodium hydride 作用下, 以 甲苯 、 mineral oil 为溶剂, 反应 8.0h, 以81.4%的产率得到哌泊溴烷
    参考文献:
    名称:
    一种溴丙哌嗪化合物的光催化合成方法
    摘要:
    本发明公开了一种溴丙哌嗪化合物的光催化合成方法,以溴丙醇和哌嗪为原料,在含氧气氛、有机溶剂、碱、过渡金属氧化物/C3N4复合光催化剂存在的条件下,经光催化反应制得溴丙哌嗪化合物。本发明以溴丙醇为原料,避免了使用SOCl2,绿色经济制备溴丙哌嗪化合物。
    公开号:
    CN114105909A
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS ET COMPOSITIONS COMPRENANT DES INHIBITEURS DES CDK ET MÉTHODES DE TRAITEMENT DU CANCER
    申请人:UNIV GEORGIA STATE RES FOUND
    公开号:WO2010129858A1
    公开(公告)日:2010-11-11
    Disclosed herein are compounds suitable for use as antitumor agents, methods for treating cancer wherein the disclosed compounds are used in making a medicament for the treatment of cancer, methods for treating a tumor comprising, administering to a subject a composition comprising one or more of the disclosed cytotoxic agents, and methods for preparing the disclosed antitumor agents.
    本文披露了适用作抗肿瘤药剂的化合物,用于治疗癌症的方法,其中所披露的化合物用于制备治疗癌症的药物,治疗肿瘤的方法包括向受试者施用包含一种或多种所披露的细胞毒性药剂的组合物,以及制备所披露的抗肿瘤药剂的方法。
  • [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON
    申请人:BIOCAD JOINT STOCK CO
    公开号:WO2018092047A1
    公开(公告)日:2018-05-24
    The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.
    本发明涉及一种新的化合物,其化学式为I:或其药学上可接受的盐、溶剂化合物或立体异构体,其中:V1为C或N,V2为C(R2)或N,如果V1为C,则V2为N,如果V1为C,则V2为C(R2),或者如果V1为N,则V2为C(R2);每个n,k独立地为0或1;每个R2,R11独立地为H,D,Hal,CN,NR'R",C(O)NR'R",C1-C6烷氧基;R3为H,D,羟基,C(O)C1-C6烷基,C(O)C2-C6烯基,C(O)C2-C6炔基,C1-C6烷基;R4为H,Hal,CN,CONR'R",羟基,C1-C6烷基,C1-C6烷氧基;L为CH2,NH,O或化学键;R1从包括的片段组中选择:片段1,片段2,片段3,每个A1,A2,A3,A4独立地为CH,N,CHal;每个A5,A6,A7,A8,A9独立地为C,CH或N;R5为H,CN,Hal,CONR'R",C1-C6烷基,未取代或被一个或多个卤素取代;每个R'和R"独立地从包括H,C1-C6烷基,C1-C6环烷基,芳基的组中选择;R6从组中选择:[化学式II]每个R7,R8,R9,R10独立地为乙烯基,甲基乙炔基;Hal为CI,Br,I,F,具有布鲁顿酪氨酸激酶(Btk)抑制剂的性质,以及含有这种化合物的药物组合物,以及它们作为治疗疾病和紊乱的药物的用途。
  • [EN] BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
    申请人:PFIZER
    公开号:WO2014068527A1
    公开(公告)日:2014-05-08
    Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
    本文披露了一种与Bruton's酪氨酸激酶(BTK)形成共价键的化合物。公开了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。公开了使用BTK抑制剂的方法,单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症,包括淋巴瘤,以及炎症性疾病或症状的方法。 (化学式I)
  • [EN] A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS<br/>[FR] CONJUGUÉ D'UN AGENT CYTOTOXIQUE À UNE MOLÉCULE DE LIAISON CELLULAIRE AVEC DES LIEURS RAMIFIÉS
    申请人:HANGZHOU DAC BIOTECH CO LTD
    公开号:WO2020257998A1
    公开(公告)日:2020-12-30
    Provided is a conjugation of cytotoxic drug to a cell-binding molecule with a side-chain linker. It provides side-chain linkage methods of making a conjugate of a cytotoxic molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and immunological disorders.
    提供了一种将细胞毒性药物与一个侧链连接分子结合的共轭物。它提供了制备细胞毒性分子与细胞结合配体的共轭物的侧链连接方法,以及在靶向治疗癌症、感染和免疫性疾病中使用该共轭物的方法。
  • [EN] CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES<br/>[FR] DÉRIVÉ DE DIMÈRE DE PYRROLOBENZODIAZÉPINE RÉTICULÉ (PBD) ET SES CONJUGUÉS
    申请人:HANGZHOU DAC BIOTECH CO LTD
    公开号:WO2020006722A1
    公开(公告)日:2020-01-09
    A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.
    一种新型的交联细胞毒剂,吡咯苯并二氮杂环二聚体(PBD)衍生物,以及它们与细胞结合分子的结合物,一种制备这些结合物的方法以及这些结合物的治疗用途。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台